Capricor Therapeutics Inc (CAPR) was Initiated by ROTH Capital to “Buy”. ROTH Capital advised their investors in a research report released on Jun 15, 2016.
Capricor Therapeutics Inc opened for trading at $3.31 and hit $3.54 on the upside on Tuesday, eventually ending the session at $3.54, with a gain of 3.81% or 0.13 points. The heightened volatility saw the trading volume jump to 21,499 shares. Company has a market cap of $64 M.
In a different news, on Mar 21, 2016, Linda Marban (CEO) purchased 10,152 shares at $2.40 per share price. According to the SEC, on Mar 21, 2016, Anthony Bergmann (Vice President of Finance) purchased 2,030 shares at $2.40 per share price. On Aug 21, 2015, Louis J Grasmick (director) purchased 11,900 shares at $4.15 per share price, according to the Form-4 filing with the securities and exchange commission.
Capricor Therapeutics Inc. is a development-stage biopharmaceutical company. The Company develops and commercializes regenerative medicine and large molecule products for the treatment of disease with a primary focus on cardiovascular diseases. The Company has six drug candidates in stages of development which include CAP-1002 CAP-1001 CSps Exosomes Cenderitide (CD-NP) and CU-NP. The Company’s technology is based in cardiospheres (CSps) which are multi-cell clusters of cardiac derived cells. The Company’s product candidate the cardiosphere-derived cells (CDC) is the single cell monolayer product of the CSps. Both CSps and CDCs are derived from a deceased human donor (allogeneic source) or from heart tissue taken directly from recipient patients themselves (autologous source).